FATE THERAPEUTICS INC (FATE)
FATE THERAPEUTICS INC (FATE)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | NaN | 6,646 | NaN | NaN |
| Total operating expenses | NaN | 154,350 | NaN | NaN |
| Loss from operations | NaN | -147,704 | NaN | NaN |
| Interest income | NaN | 11,052 | NaN | NaN |
| Change in fair value of stock price appreciation milestones | NaN | -127 | NaN | NaN |
| Other income | NaN | 93 | NaN | NaN |
| Impairment of long-lived assets | NaN | 0 | NaN | NaN |
| Total other income | NaN | 11,389 | NaN | NaN |
| Loss on disposal of property and equipment | NaN | -45 | 0 | 36 |
| Net loss | -31,213 | -32,374 | -32,250 | -71,691 |
| Depreciation and amortization | 2,918 | 3,063 | 3,227 | 6,611 |
| Stock-based compensation | 3,929 | 5,528 | 4,861 | 14,535 |
| Accretion and amortization of premiums and discounts on investments, net | 772 | 881 | 810 | 1,915 |
| Deferred revenue | 200 | 377 | 4 | -393 |
| Change in fair value of stock price appreciation milestones | 80 | -127 | 90 | -207 |
| Accounts receivable | -212 | 233 | -713 | -2,144 |
| Prepaid expenses and other assets | -132 | -1,014 | -1,026 | -3,139 |
| Accounts payable and accrued expenses | -5,774 | 865 | -550 | -9,342 |
| Right-of-use assets and lease liabilities, net | -534 | -591 | -685 | -1,241 |
| Net cash used in operating activities | -30,822 | -23,314 | -24,374 | -58,396 |
| Proceeds from sale of property and equipment | NaN | 237 | 3 | 122 |
| Purchases of property and equipment | 239 | 1,192 | 2,203 | 2,558 |
| Purchases of investments | 28,729 | 37,731 | 57,975 | 99,437 |
| Maturities of investments | 52,555 | 66,316 | 81,447 | 164,137 |
| Net cash provided by investing activities | 23,587 | 27,630 | 21,272 | 62,264 |
| Issuance of common stock from equity incentive plans, net of issuance costs | NaN | 0 | 0 | 0 |
| Proceeds from public offering of common stock, net of issuance costs | NaN | 0 | 0 | 0 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | NaN | 0 | 0 | 0 |
| Proceeds from ft819 cirm award | NaN | 1,490 | 0 | 0 |
| Proceeds from ft836 cirm award | NaN | -200 | -2,475 | -1,325 |
| Net cash provided by financing activities | NaN | 1,690 | 2,475 | 1,325 |
| Net change in cash, cash equivalents and restricted cash | -7,235 | 6,006 | -627 | 5,193 |
| Cash, cash equivalents and restricted cash at beginning of the period | 56,855 | 50,849 | 46,283 | NaN |
| Cash, cash equivalents and restricted cash at end of the period | 49,620 | 56,855 | 50,849 | NaN |